Molecular alterations associated with cyclin D1 overexpression in endometrial cancer

International Journal of Cancer

Volumn 110, Issue 2, 2004, Pages 194-200

  Moreno Bueno, Gema ^a   Rodríguez Perales, Sandra ^a   Sánchez Estévez, Carolina ^a   Marcos, Raquel ^b   Hardisson, David ^b   Cigudosa, Juan C ^a   Palacios, José ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

catenin; Amplification; CCND1; Cyclin D1 expression; Endometrial carcinoma; K RAS; Mutation; PTEN

Indexed keywords

BETA CATENIN; CYCLIN D1; MICROSATELLITE DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAS PROTEIN;

ARTICLE; CCND1 GENE; CONTROLLED STUDY; CYTOPLASM; ENDOMETRIUM CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

BETA CATENIN; CYCLIN D1; CYTOSKELETAL PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, P53; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE REPEATS; PHOSPHORIC MONOESTER HYDROLASES; TRANS-ACTIVATORS;

EID: 2342614719     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20130     Document Type: Article

References (49)

1. 1-phase progression. Genes Dev 1999;13:501-12.
2. Winston JT, Coats SR, Wang YZ, Pledger WJ. Regulation of the cell cycle machinery by oncogenic Ras. Oncogene 1996;12:127-34.
3. 1 arrest by downregulating cyclin D1 via its protein phosphatase activity and upregulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 2001;10:599-604.
4. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
5. Shtutman M, Zhurinskym J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the B-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999;96:5522-7.
6. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
7. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS. Overexpression of cyclin D1 mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995;1:1257-60.
8. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115-27.
9. Simpson, JF, Quan DE, O'Malley F, Odom-Maryon T, Clarke PE. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol 1997;151:161-8.
10. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999;5:1966-75.
11. Hoechtlen-Vollmar W, Menzelm G, Bartl R, Lamerz R, Wick M, Seidel D. Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance. Br J Haematol 2000;109:30-8.
12. Kaltz-Wittmer C, Klenk U, Glaessgen A, Aust DE, Diebold J, Lohrs U, Baretton GB. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 2000;80:1455-64.
13. Matías-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, Prat J. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-77.
14. Nikaido T, Li SF, Shiozawa T, Fujii, S. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 1996;78:1248-53.
15. Schmitz MJ, Hendricks DT, Farley J, Taylor RR, Geradts J, Rose GS, Birrer MJ. p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma. Gynecol Oncol 2000;77:439-45.
16. Soslow RA, Shen PU, Chung MH, Isacson C, Baergen RN. Cyclin D1 expression in high-grade endometrial carcinomas: association with histologic subtype. Int J Gynecol Pathol 2000;19:329-34.
17. Tsuda H, Yamamoto K, Inoue T, Uchiyama I, Umesaki N. The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br J Cancer 2000;82:675-82.
18. Cao QJ, Einstein MH, Anderson PS, Runowicz CD, Balan R, Jones JG. Expression of COX-2, Ki-67, Cyclin D1, and p21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol 2002;21:147-54.
19. Ruhul Quddus M, Latkovich P, Castellani WJ, James Sung C, Steinhoff MM, Briggs RC, Miranda RN. Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. Arch Pathol Lab Med 2002;126:459-63.
20. Machin P, Catasus L, Pons C, Munoz J, Matias-Guiu X, Prat J. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 2002;33:206-12.
21. Moreno-Bueno G, Rodríguez-Perales S, Sánchez-Esté vez C, Hardisson D, Sarrió D, Prat J, Cigudosa JC, Matias-Guiu X, Palacios J. Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 2003;22:6115-8.
22. Moreno-Bueno G, Hardisson D, Sánchez C, Sarrio D, Cassia R, Garcia-Rostan G, Prat J, Guo M, Herman JG, Matias-Guiu X, Esteller M, Palacios J. Abnormalities of the APC/β-catenin pathway in endometrial cancer. Oncogene 2002;21:7981-90.
23. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T, Wallin G, Parsons R, Longy M, Larsson C, Eng C. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 1997;57:4710-3.
24. Chen J, Heerdt BG, Augenlicht LH. Presence and instability of repetitive elements in sequences the altered expression of which characterizes risk for colonic cancer. Cancer Res 1995;55:174-80.
25. El-Hizawi S, Lagowski JP, Kulesz-Martin M, Albor A. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer Res 2002;62:3264-70.
26. Pere H, Tapper J, Wahlstrom T, Knuutila S, Butzow R. Distinct chromosomal imbalances in uterine serous and endometrioid carcinomas. Cancer Res 1998;58:892-5.
27. Bieche I, Olivi M, Nogues C, Vidaud M, Lidereau R. Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 2002;86:580-6.
28. Shao J, Sheng H, DuBois RN, Beauchamp RD. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem 2000;275:22916-24.
29. Wong NA, Morris RG, McCondochie A, Bader S, Jodrell DI, Harrison DJ. Cyclin D1 overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not K-RAS mutation. J Pathol 2002;197:128-35.
30. Zhou XP, Kuismanen S, Nystrom-Lahti M, Peltomaki P, Eng C. Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. Hum Mol Genet 2002;11:445-50.
31. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-4.
32. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40.
33. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-8.
34. Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 1999;59:462-6.
35. Cohn DE, Basil JB, Venegoni AR, Mutch DG, Rader JS, Herzog TJ, Gersell DJ, Goodfellow PJ. Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. Gynecol Oncol 2000;79:101-6.
36. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, Petersen E, Kinzler K, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-6.
37. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-30.
38. Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61:4311-4.
39. Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A, Aaltonen LA, Eng C. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 2002;161:439-47.
40. Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol 2003;23:6139-49.
41. 1 cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res 2001;61:4569-75.
42. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001;158:2097-106.
43. INK4A and is a region of low proliferation. Am J Pathol 2001;159:1613-7.
44. Ishigaki K, Namba H, Nakashima M, Nakayama T, Mitsutake N, Hayashi T, Maeda S, Ichinose M, Kanematsu T, Yamashita S. Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 2002;87:3433-40.
45. Qiao Q, Ramadani M, Gansauge S, Gansauge F, Leder G, Beger HG. Reduced membranous and ectopic cytoplasmic expression of beta-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int J Cancer 2001;95:194-7.
46. Provost E, Yamamoto Y, Lizardi I, Stern J, D'Aquila TG, Gaynor RB, Rimm DL. Functional correlates of mutations in beta-catenin exon 3 phosphorylation sites. J Biol Chem 2003;278:31781-9.
47. Hosokawa Y, Suzuki R, Joh T, Maeda Y, Nakamura S, Kodera Y, Arnold A, Seto M. A small deletion in the 3′-untranslated region of the cyclin D1/PRAD1/bcl-1 oncogene in a patient with chronic lymphocytic leukemia. Int J Cancer 1998;76:791-6.
48. Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 2002;62:2447-54.
49. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12:3499-511.